Back to Search

A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma


  • Protocol Number: 201811079
  • Principal Investigator: Pachynski, Russell
  • Cancer Types: GU: Bladder, Kidney, Prostate, Testicular

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

Protocol Interventions